Industry News
Biotechnology Industry News
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington’s trial
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial ntaylor Tue, 01/18/2022 - 05:37
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letter
'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letter klahucik Fri, 01/14/2022 - 10:33
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letter
'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letter klahucik Fri, 01/14/2022 - 10:33
JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space
JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space aarmstrong Fri, 01/14/2022 - 09:49
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish ntaylor Fri, 01/14/2022 - 07:04
EMA sets out plan to accelerate clinical trials, reduce administrative burden
EMA sets out plan to accelerate clinical trials, reduce administrative burden ntaylor Fri, 01/14/2022 - 05:47
FDA denies Denali’s Takeda-partnered Alzheimer’s drug from entering clinic
FDA denies Denali's Takeda-partnered Alzheimer's drug from entering clinic klahucik Thu, 01/13/2022 - 09:04
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy ntaylor Thu, 01/13/2022 - 08:27
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker chale Thu, 01/13/2022 - 08:25
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex’s cystic fibrosis dominance
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex's cystic fibrosis dominance chale Thu, 01/13/2022 - 08:25
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets ntaylor Thu, 01/13/2022 - 07:48
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new drugs; Roche launches smart, point-of-care glucose monitor
JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor aarmstrong Wed, 01/12/2022 - 08:27
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor aarmstrong Wed, 01/12/2022 - 08:27
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson’s field
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson's field ntaylor Wed, 01/12/2022 - 08:16
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development ntaylor Wed, 01/12/2022 - 06:09
Sana links arms with IASO, Innovent in $204M biobucks pact to use CAR construct in up to 6 cell and gene therapies
Sana links arms with IASO, Innovent in $204M biobucks pact to use CAR construct in up to 6 cell and gene therapies klahucik Tue, 01/11/2022 - 12:26
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND ntaylor Tue, 01/11/2022 - 08:14
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis badams Tue, 01/11/2022 - 04:50
JPM22, Day 2: Sage’s double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than never for Enanta in COVID
JPM22, Day 2: Sage's double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than never for Enanta in COVID badams Tue, 01/11/2022 - 04:50
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15% klahucik Mon, 01/10/2022 - 11:50